Last reviewed · How we verify
Sotalol Oral Tablet
At a glance
| Generic name | Sotalol Oral Tablet |
|---|---|
| Also known as | sotalol choridrate |
| Sponsor | University of Sao Paulo General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
- Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers (PHASE1)
- Safety Assessment for Sotalol Protocol in Outpatient Unit (PHASE4)
- Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sotalol Oral Tablet CI brief — competitive landscape report
- Sotalol Oral Tablet updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI